Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 October 2018 | Story UFS | Photo Sonia Small
Kovsies Dream Team takes the netball crown
The Dream Team from the UFS celebrate their victory after beating Tuks by 63-59 in the final of the Varsity Netball competition.


Photo Gallery

The Kovsie netball team has the Varsity Netball trophy, one of the most prestigious in university sport, back in the cabinet. With this, they are now the most successful team in the history of the competition, having won three (2013, 2014 and 2018) of the six titles.

The Dream Team earned the prize thanks to a brilliant performance in the final against the defending champs, Tuks, winning by 63-59 in front of a sold-out Callie Human Centre on Monday 8 October 2018. It was the first final staged in Bloemfontein.

The Kovsies was in the lead after each quarter, but Tuks seemed to ascend in the final quarter, leading by 49-46 with nine minutes remaining. The home team then called the power play (when goals score two points) and during a golden five minutes, they built up a 63-55 lead to seal the match.

It was a brilliant turnaround for the Dream Team after losing twice to the same team in July – with 10 and 18 goals.

“The team played excellently, and I am so proud of their performance. I watched them perform throughout this year’s Varsity Netball series and want to congratulate them on their victory on behalf of the university’s executive management and the entire university community,” said Prof Francis Petersen, Rector and Vice-Chancellor of the University of the Free State. 

“There’s nothing greater than playing for a great team that supports you and trusts you; thus, every time you go on court you want to give your all for them,” said Khanyisa Chawane, who played centre and wing attack in the final.

“We came a long way; there was no way we were going to give it away once we got to the final. Kovsies have a legacy and this is a legacy we want to carry through.”

Chawane was named the Player of the Tournament. She is the first player to be awarded the best player title in the Premier League, National Championship, and Varsity Netball in the same year.

Centre-court player Sikholiwe Mdletshe also referred to the legacy.

“We are starting our legacy, we knew we had to win, other teams can’t come here and dominate.”

“It is such an honour, the fact that we could do it in front of our home crowd support. We waited very long for this,” said captain Alicia Puren, who played in her final game after five seasons with the Kovsies.

According to Burta de Kock, the coach, the players used the power play in the final quarter very well in which they scored eight goals to four.  “We spoke a lot about being calm and keeping position in those two minutes.” De Kock said the large crowd was a huge advantage. “We’ve never had such a massive crowd before. It definitely helped us.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept